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ABSTRACT
Norovirus infections have been described as self-limiting diseases of short duration. An investigation of
a norovirus outbreak in a university hospital provided evidence for severe clinical features in patients
with several underlying diseases. Clinical outcomes of norovirus infection were deﬁned. Risk-factor
analysis targeting underlying diseases and medication was performed using multivariate analyses. In
ﬁve outbreak wards, 84 patients and 60 nurses were infected (an overall attack rate of 32% in patients,
and 76% in nurses). The causative agent was the new variant Grimsby virus. Severe clinical features,
including acute renal failure, arrhythmia and signs of acute graft organ rejection in renal transplant
patients, were observed in seven (8.3%) patients. In multivariate analyses, cardiovascular disease (OR
17.1, 95% CI 2.17–403) and renal transplant (OR 13.0, 95% CI 1.63–281) were risk-factors for a potassium
decrease of >20%. Age >65 years (OR 11.6, 95% CI 1.89–224) was a risk-factor for diarrhoea lasting
>2 days. Immunosuppression (OR 5.7, 95% CI 1.78–20.1) was a risk-factor for a creatinine increase of
>10%. Norovirus infections in patients with underlying conditions such as cardiovascular disease, renal
transplant and immunosuppressive therapy may lead to severe consequences typiﬁed by decreased
potassium levels, increased levels of C-reactive protein and creatine phosphokinase. In the elderly,
norovirus infection may lead to an increased duration of diarrhoea. Therefore patients at risk should be
hospitalised early and monitored frequently. Strict preventional measures should be implemented as
early as possible to minimise the risk of nosocomial outbreaks.
Keywords Cardiovascular disease, clinical complications, elderly patients, immunocompromised patient, noro-
virus infections, renal transplant
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INTRODUCTION
Norovirus (former Norwalk-like virus) infection,
well-known as ‘winter vomiting disease’, has
been described as a short self-limiting disease
characterised by sudden onset of nausea, vomit-
ing and diarrhoea. In adult volunteer studies and
investigations of previously healthy individuals
[1–6], clinical symptoms such as abdominal pain,
nausea, vomiting, headache and chills have been
reported. In many outbreak investigations, the
mild self-limiting character of the illness associ-
ated with norovirus infection has been empha-
sised.
In 2002, unusually high numbers of norovirus
infections were reported in Germany [7] and
elsewhere [8,9]. Compared with 2001, the
incidence of norovirus infection in Germany
increased ﬁve-fold from 11 cases ⁄ 100 000 popu-
lation to 57 cases ⁄ 100 000 population. The peak
incidence was attributed to outbreaks occurring
during the winter (weeks 41–53). During this
period, outbreaks affected wards at a university
hospital in northern Germany. The ﬁrst outbreak
occurred in a closed psychiatric ward in Novem-
ber, but the epidemic subsequently reached four
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other sections of the hospital, with particularly
severe problems in the departments of cardiology
and nephrology. This report describes the impact
of norovirus infection in these settings, which was
much greater than was anticipated on the basis of
information published previously.
MATERIALS AND METHODS
Case deﬁnition
Between 1 November 2002 and 31 January 2003, all patients
and staff members from one of the ﬁve studied outbreak wards
who were affected with a sudden onset of diarrhoea (three or
more episodes of loose stools in a 24-h period and ⁄or vomiting
[10]), were included as cases. Cases were considered to be
norovirus-positive if samples from at least two patients from
the same ward were positive by norovirus-speciﬁc RT-PCR
tests. As all the included patients and staff members came
from ﬁve wards, they were regarded as epidemiologically
linked to each other within each ward. Patients admitted with
clinical signs were regarded as index cases, and patients
admitted ‡48 h before developing clinical signs were regarded
as nosocomial cases.
Data collection
Data were collected prospectively during the outbreaks. The
attack rate of the patients or staff members of each ward was
calculated by dividing the number of cases in each group by
the total number of patients or staff members potentially at
risk. The population at risk was deﬁned as all individuals
working in or admitted to the ward in the period from the
onset of clinical symptoms of the ﬁrst patient until 2 days
after the last patient became symptom-free. For the calcula-
tion of nosocomial incidence, index cases (patients) were
ignored.
Staff members were interviewed and patient charts were
reviewed to assess patient history (underlying disease) and
clinical signs such as diarrhoea and vomiting. Data were also
collected concerning potassium, creatinine and C-reactive
protein (CRP) levels, radiological examinations (abdominal
X-rays), histology (renal biopsy), other invasive procedures,
therapeutic measures taken (rehydration therapy, immuno-
suppressive therapy, use of metoclopramide and loperamide)
and indicators of complications (haemodialysis, death, renal
biopsy). For one patient, clinical data were not available.
Risk-factor analysis
The following potential risk-factors were analysed: age >65
years; gender; underlying disease (cardiovascular disorders,
pulmonary disorders, gastroenterological disorders, autoim-
mune disease, malignancy, trauma, psychiatric disorder, renal
disorder, renal transplant, haemodialysis); immunosuppres-
sion (steroids, methotrexate, cyclosporine A, tacrolimus, etc.);
and symptomatic treatment (metoclopramide and loper-
amide). Nosocomial acquisition of the infection was also
included in the analysis. Relapses were deﬁned as a new
period of either diarrhoea or vomiting after a symptom-free
interval of ‡48 h. Three norovirus-positive patients were
excluded from risk-factor analyses because they were also
positive for other gastroenteric pathogens (two were positive
for Clostridium difﬁcile toxin; one was positive for adenovirus).
Only those patients with complete data for tested outcomes
were included in the analysis. Patients who were norovirus-
negative were also included because norovirus was the most
likely pathogen according to their epidemiological setting (in
place and time) and because no other pathogens were detected
despite careful diagnostic procedures. Furthermore, as most of
the ‘negative’ stool specimens were sent to the laboratory
when symptoms had already resolved, it was concluded that
these patients were probably no longer shedding norovirus.
Laboratory diagnostics
Stool specimens were assayed for the presence of noroviruses
by nested RT-PCR as described previously [11]. For conﬁrma-
tion and strain characterisation, samples were sent to the
National Institute of Public Health and the Environment
(RIVM), Bilthoven, The Netherlands. Samples were assayed
for virus RNA, and PCR products were sequenced as des-
cribed previously [12]. Sequences were aligned using the
database of the Foodborne Viruses in Europe project [13]. In
addition, all stool specimens were cultured for enteropatho-
genic bacteria, assayed for C. difﬁcile toxin, and investigated
for viral pathogens by electron-microscopy.
Statistical analysis
Categorical variables were compared using chi-square or
Fisher’s exact test; ORs and 95% CIs were calculated using
Epi Info v.6.04c (CDC, Atlanta, GA, USA). All variables were
evaluated by multiple logistic regression analysis with step-
wise variable selection for inclusion in the ﬁnal logistic
regression model. SAS software was used for all multivariate
analyses (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Epidemiology
The ﬁve wards involved in the outbreak
belonged to the psychiatry, nephrology, gastro-
enterology, cardiology and trauma departments.
In total, 84 patients met the clinical and epide-
miological case deﬁnition of norovirus infection,
and 72 patients acquired their infection nosoco-
mially. Analysis of the outbreaks in each ward
showed patterns characteristic of person-to-per-
son transmission, except for the trauma ward, in
which there were many cases apparent on the
ﬁrst day, followed by a pattern characteristic of
person-to-person transmission on subsequent
days. Food- or water-borne transmission were
ruled out because all other unaffected wards of
the hospital received food and water from the
same sources. Thirteen patients were admitted
with the disease from the community.
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Stool specimens from 41 patients were assayed
by norovirus RT-PCR. Most (n = 27; 66%) were
positive, but 14 (34%) were negative. Each case
patient from whom no stool specimen was avail-
able, or who had a negative norovirus PCR, was
linked epidemiologically to conﬁrmed cases. Four
samples were referred to RIVM for conﬁrmatory
testing and sequencing. All sequences were iden-
tical, and clustered with the new variant Grimsby
virus [14]. Bacterial cultures of all stool specimens
failed to yield enteropathogenic bacteria. Apart
from three patients who were excluded from risk-
factor analysis, all other stool specimens tested
were negative for C. difﬁcile toxin and other
viruses.
In total, 79 staff members were involved (60
nurses, 19 other staff members). The attack rate in
nurses was twice as high as the attack rate in the
patient group (Table 1) (p < 0.001). Because this
was unusual, staff were interviewed to assess
possible common sources of exposure. There were
no meetings in or outside the clinic with the
potential for common food consumption. Attack
rates in other staff members could not be deter-
mined because they were responsible for several
wards and therefore the denominator population
was variable.
Clinical symptoms and complications
Staff members had self-limiting vomiting or diar-
rhoea, or both, for episodes lasting <48 h. Only
one nurse required admittance to the hospital for
symptomatic treatment with intravenous saline.
The main clinical feature with patients was
diarrhoea, which affected 94% of patients. Only
68% of the patients developed vomiting (Table 2).
The median duration of clinical symptoms was
1 day (range 1–7 days). In total, 38 (45%) patients
were treated with intravenous saline infusions.
The severity of dehydration in two patients led to
somnolence; they had been drowsy, but were
arousable to normal level at admission. Of 22
patients with increased serum creatinine levels,
three required haemodialysis. Creatinine levels in
the outbreak population increased by a mean of
35% (SD ± 25.7%). The median increase in serum
creatine was 23 lmol ⁄L during the infection
episode. Diarrhoea and vomiting also led to
potassium loss, with potassium decreases of
>10% in 18 patients, and >20% in seven patients.
CRP levels were available for 57 patients (mean
CRP level of 68.5 mg ⁄L; SD ± 55 mg ⁄L; median
58 mg ⁄L; normal <5 mg ⁄L).
One patient, suffering from ventricular tachy-
cardias, developed three episodes of ventricular
tachycardias and needed a cardioversion.
Another patient could not reach the bathroom in
time, slipped while vomiting and fell, suffering
bruises. In two renal transplant patients, immu-
nosuppressive therapy with sirolimus and myco-
phenolate mofetil hydrochloride had to be
stopped because diarrhoea led to fever and severe
dehydration, with instability of the cardiovascular
system. No patient died while clinical signs of
Table 1. Attack rates of norovirus infections in affected wards
Ward
No of index
patients (community-
acquired cases)
Nosocomial cases/
patients on the ward
during the outbreak
period
Nosocomial
incidence
(patients)
Attack rate
(patients)
Infected nurses/
number of nurses
working during the
outbreak period
Attack rate
(nurses) p (attack rates)a
Psychiatry 1 17 ⁄ 23 74% 78% 13 ⁄ 17 76% 1.0
Nephrology 15 ⁄ 17 88% <0.0001
First period 4 14 ⁄ 56 25% 32%
Second period 5 9 ⁄ 42 21% 33%
Gastroenterology 2 9 ⁄ 41 22% 27% 10 ⁄ 11 90% 0.0001
Cardiology 1 11 ⁄ 26 42% 46% 7 ⁄ 16 44% 0.87
Trauma 0 11 ⁄ 31 35% 35% 15 ⁄ 18 83% 0.001
Total 13 72 ⁄ 219 33% 38% 60 ⁄ 79 76% <0.0001
aChi-square test comparing attack rates of nurses and patients; p values between different attack rates for nurses were not signiﬁcant.
Table 2. Clinical signs and symptoms of norovirus infec-
tiona
Signs and symptoms No. of patients
Diarrhoea (number of symptomatic days in total) 79 (172)
Vomiting (number of symptomatic days in total) 57 (85)
Somnolence 2
Clinical symptoms for >48 h 23
Relapses 14
Haemodialysis 3
Cardioversion 1
Serum creatinine increase of >10%b 22
Serum potassium decrease of >20%b 7
aMild clinical symptoms such as nausea, abdominal cramps and headache were not
investigated. bExcluding chronic haemodialysis patients.
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norovirus infection were apparent, but three
patients died during the following 2 weeks. The
underlying diseases of these patients were Klat-
skin-cancer (renal failure developed in this
patient), active lupus erythaematodes with ulcer-
ations of both legs (renal failure developed while
norovirus symptoms were present), and heart
failure in an elderly patient who died with severe
nosocomial pneumonia; the prognosis had been
poor for all three cases before norovirus infection.
In total, 14 patients relapsed after being symptom-
free for ‡48 h (range 3–9 days; mean 4.3 days,
SD ± 2.5 days).
Table 3 summarises the univariate and multi-
variate risk-factor analyses. Relapses or medica-
tion with metoclopramide or loperamide were not
signiﬁcant risk-factors for any deﬁned outcomes
(data not shown).
DISCUSSION
Lopman et al. [15] questioned the assumption that
norovirus gastroenteritis is a trivial disease after
analysing data from norovirus outbreaks in
England and Wales during 1992–2000. It has been
suggested that norovirus infection could become
an important factor contributing to the poor
outcome of patients already weakened by other
conditions [16]. Moreover, Lopman et al. [17]
suggested that ‘sick patients get sicker’, referring
to the length of diarrhoeal episodes for hospital-
ised patients compared with those in nursing
homes. However, no details of the burden of
disease in at-risk populations have been pub-
lished previously.
The starting point for the present investigation
was the observation of severe complications of
norovirus infection in a few patients during a
large hospital outbreak. It was noted that more
patients developed diarrhoea rather than vomit-
ing, which is in contrast to published ﬁndings [4].
However, norovirus includes a diverse group of
viruses that segregate into lineages termed geno-
groups (GG) and genotypes. Most outbreak
strains in closed settings (hospitals, nursing
homes) have been characterised as GG II, with
genotype II ⁄ 4 (Grimsby) predominating [18]. In
2002, a new variant Grimsby virus emerged
across Europe and the USA. In Europe, the
emergence was associated with a steep increase
in the total number of outbreaks reported in
almost all countries involved in the FoodborneT
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Virus in Europe network [13,14]. The outbreak in
the present study was also caused by this new
variant GGII ⁄ 4 (unpublished data). Therefore, the
pattern of illness that was observed may not be
typical of other noroviruses.
In the present study, symptomatic norovirus
infection lasted longer than expected (1–7 days)
and relapses occurred. Protective factors against a
longer duration were underlying diseases with
a low degree of immunosuppression, such as
trauma, gastrointestinal disorders and malignan-
cies. Prolonged shedding over a period of
120 days has been described previously [19] in
an intestinal transplant recipient; it was shown
that a chronic norovirus infection (GG II, geno-
type Miami Beach) was the cause, and only a
reduction in immunosuppressive therapy ended
the episodes of diarrhoea and enteritis. Unfortu-
nately, follow-up stool samples could not be
obtained in the present study. Therefore, it is
unknown whether any of the immunocompro-
mised patients developed a chronic infection.
An intriguing novel feature was the occurrence
of relapses of norovirus infections in 14 patients.
It is not clear whether these cases represented true
relapses, or a rebound of symptoms following
rehydration. However, the interval between
relapses ranged from 3 to 9 days. In one patient,
a follow-up sample was positive by RT-PCR, but
most patients were not sampled later in the course
of the disease. There was no signiﬁcant risk-factor
associated with relapses, so this effect may be
attributed to the new variant virus.
The need for haemodialysis and cardioversion
in three patients focused attention on serum
creatinine and potassium levels [20]. Surprisingly,
the effect of illness on potassium levels, serum
creatinine levels and CRP levels appeared high
for a ‘trivial’ viral infection, so these parameters
were included as outcome measures. Gendrel
et al. [21] found elevated CRP levels (>20 mg ⁄L)
in 61 (26%) of 236 children suffering from viral
gastroenteritis, whereas in the present study, 42
(73%) of 57 patients had elevated CRP levels.
Recently published data [15] suggest that com-
plications of norovirus infection arise predomin-
antly in the elderly. In the present study,
individuals aged >65 years were associated
signiﬁcantly with longer diarrhoeal episodes.
Cardiovascular disease and renal transplant
were risk-factors for potassium loss; immunosup-
pressive therapy was a risk-factor for raised
creatinine; and immunosuppressive therapy was
a risk-factor for high CRP levels. Trauma was
protective for longer diarrhoeal episodes, reﬂect-
ing the fact that these patients belonged to the
healthy population. Thus, this population may be
considered as a small internal control group;
indeed, OR were <1 for all outcomes except
‘vomiting for >1 day’, thereby providing evi-
dence that healthy individuals develop predomi-
nantly mild symptoms.
In the present study, only 27 of 84 patients
tested positive for norovirus. During an ongoing
outbreak, it is not possible to obtain stool speci-
mens from all patients involved; patients caring
for themselves often forget to obtain specimens,
and the wards involved were advised to dis-
charge patients as early as possible. Hence,
patients with a short course of infection might
not have had the opportunity to provide speci-
mens. Furthermore, norovirus-negative patients
often submitted specimens after the symptoms
had resolved, indicating that norovirus did not
persist for long periods in these patients. Never-
theless, the possibility cannot be discounted that
either a small group of norovirus-negative pa-
tients might have been included in the study, or
that norovirus-positive patients without symp-
toms were missed.
Another limitation concerns the patient groups
investigated. The outbreak was conﬁned to only
ﬁve wards from ﬁve different departments. Con-
sequently, only patients from these departments
were investigated. Thus, data are lacking for other
patient groups, particularly haematological,
pneumological, surgical and paediatric patients.
There were marked differences in attack rate,
perhaps depending on factors associated with the
ward and staff group. For example, dementia
patients, for whom isolation procedures are dif-
ﬁcult to establish, were treated on the psychiatric
ward. In contrast to attack rates reported by the
CDC [9], nursing staff were at higher risk of
infection compared with patients, perhaps be-
cause the present study only included staff
members who had been working on the ward
during the outbreak period in the denominator
population. In cardiology, educational interven-
tions concerning the prevention of transmission of
noroviruses were started at an early stage, which
may have resulted in the lowest attack rate.
The outbreak investigation demonstrated
that ‘sick patients got sicker’ when acquiring a
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norovirus infection. Furthermore, at-risk popula-
tions were identiﬁed for several clinical outcomes.
Patients with cardiovascular disease, those receiv-
ing immunosuppressive therapy, the elderly and
organ transplant recipients were at higher risk of
a severe clinical outcome. These patients should
be monitored frequently when suffering from
norovirus infection.
Although many recommendations exist for pre-
venting transmission of noroviruses [22], the
potentially severe impact of norovirus outbreaks
in frail hospital populations has been underesti-
mated. An important recommendation should
focus on prevention of such outbreaks in hospitals,
especially when immunocompromised patients
are treated. Immunocompromised patients should
be educated about possible severe courses of
‘trivial’ gastrointestinal infections, and should be
instructed to consult a physician as early as
possible to allow monitoring for possible compli-
cations. The present ﬁndings underline the import-
ance of applying stringent infection control
measures when dealing with norovirus infections.
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